Besides generics, Dr. Reddy’s has committed a lot of resources to develop its biosimilars as well as new chemical entity business. Biosimilars have been seen as a growth engine for large, capable ...

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market. The tablets, bioequivalent to Otsuka's Jynarque, will be manufactured at ...

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Receiving a generic version of Ozempic or Wegovy from a compounding pharmacy is normally both easier to access and cheaper.

By understanding a patient’s unique genetic profile, biomarker readings and lifestyle information, doctors could tailor the ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug ... Nordisk's head of ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has ... relative survival rate of only around 6%. In a related development, the FDA has also cleared a CLDN18.2 diagnostic ...